Key points from article :
London start-up launches Car-T clinical trials.
Carrying out three Car-T (chimeric antigen receptor T-cell) studies.
Autologous treatments engineer the patients’ own immune cells to recognise and kill cancer cells.
40 companies are working on similar living drug treatments.
Dual targeting approach may give Autolus a competitive edge.
Company was spun out of University College London in 2014.
